Long-Term Foramen Ovale Closure after Cryptogenic Stroke

Patent foramen ovale closure is the standard treatment for cryptogenic stroke patients. However, there are is little information on its long-term evolution.

DEFENSE-PFO: el cierre FOP con ciertas características disminuye eventos combinados y strokeThe aim of this study was to determine clinical outcomes (death, ischemic or bleeding events) after foramen ovale closure over a 10-year evolution.

 

The study included 201 consecutive patients (mean age 47 ± 12, 51% women) receiving transcatheter patent foramen ovale closure in the context of cryptogenic stroke (stroke: 76%, transient ischemic attack: 32%, systemic embolism: 1%). Data on ischemic and bleeding events, and on antithrombotic drugs, was collected over mean 12 years (range 10 to 17) and follow-up was completed in 96% of the population.


Read also: New Device for More Protection in Carotid Artery Stenting.


The closure device was successfully implanted in all cases, with residual shunt in 3.3% of patients at echocardiographic follow-up.

 

At total 13 patients died at follow-up (all of non-cardiac cause); 2 patients presented non-disabling stroke and 6 presented transient ischemic attack (0.08 strokes/100 patients/year).

 

15% of the cohort presented a history of thrombophilia, which tended to be associated to more ischemic events at follow-up (p=0.067).


Read also: Is Tricuspid Regurgitation after TAVR Significant?


Bleeding events occurred in 13 patients; 4 were major bleeding events (intracranial). They were all under aspirin at the time.

 

A total 42 patients stopped the antithrombotic treatment at mean 6 months after foramen ovale closure and no patient presented events (ischemic or hemorrhagic) after 10 ± 4-year follow-up.

 

Conclusion

Foramen ovale closure was associated with a very low rate of ischemic events (<1% stroke) over 10 years after procedure. Major bleeding occurred in 2% of the population (all patients were under antiaggregants).

 

Patients that suspended all antithrombotic medication (mostly within a year after patent foramen ovale closure) presented no ischemic or bleeding events at long term follow-up.

 

Original title: Long-Term Follow-Up After Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism.

Reference: Jérôme Wintzer-Wehekind et al. J Am Coll Cardiol 2019;73:278–87.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...